Biotech Values

[DewDiligence]

INHX’s INX-189 has started phase-1:

http://finance.yahoo.com/news/Inhibitex-Reports-First-bw-1492284419.html?x=0&.v=1

The Company announced that it has initiated a Phase I double-blind, placebo-controlled, single ascending dose study to evaluate the safety and pharmacokinetics of INX-189 in healthy volunteers… The study, which is being conducted in the U.S., will evaluate up to six escalating doses of INX-189, ranging from 3 mg up to 200 mg. Each dose cohort will include eight subjects, six of which will receive INX-189 and two that will receive placebo.

As noted in #msg-48567678, INX-189 is similar to IDIX’s IDX184 in structure and MoA.